Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment
Aging, Dementia, and Behavioral Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
10-004

Gauge interest and acceptance of the use of passive technology for monitoring of cognition.

The lack of biomarkers for early-stage disease is a barrier for the development of effective therapeutics against cognitive decline. Technology may afford multiple ways to passively monitor cognitive function. While these methods may be sensitive to early cognitive changes, public opinion would be critical to implementation. To begin to understand public opinion of cognitive monitoring through technology, we conducted a survey.

Participants completed an internet-based survey. Surveys were distributed electronically within the U.S. (in English) via the UMass Conquering Diseases program. Surveys were also distributed via social media in Costa Rica (in Spanish) to obtain data on a different population.

58.1% of U.S. respondents (n=173) would be highly likely to agree to passive monitoring of cognition via a smartphone application. Higher degree of experience with technology made participants more likely to agree to monitoring (p=0.003). Healthcare professionals were less likely to agree to monitoring (p=0.012). The primary concern was privacy (p<0.01). Sex, age, education level, a diagnosis of dementia in the respondent or a relative, and perceived cognition compared to 10 years prior did not affect the participant’s likelihood of agreeing to monitoring. We compared these surveys via logistic regression to those answered in Costa Rica (n=43, total n=216), adjusting for age, education level, healthcare profession, owning a smartphone, knowledge in technology, and perception of cognitive decline. Respondents in Costa Rica were 7 times more likely to agree to monitoring (p<0.01). Respondents in the U.S. were 5 times more likely to be concerned about the impact on health insurance (p=0.001) and life insurance (p=0.01). 

Understanding the public perception and ethical implications of passive monitoring via technology should guide the design of such tools. Furthermore, such designs should take into account the particular viewpoints of each society.

Authors/Disclosures
Sylvia Josephy, MD (Caja Costarricense de Seguro Social)
PRESENTER
Dr. Josephy has nothing to disclose.
Kara M. Smith, MD, FÂé¶¹´«Ã½Ó³»­ (Boston Medical Center) Dr. Smith has received personal compensation in the range of $0-$499 for serving as a Consultant for PureTech. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Altec Inc. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal Pharmaceuticals. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Massachusetts Board of Medicine. The institution of Dr. Smith has received research support from NIH. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a single time expert panel discussion contributor with Acadia.